Supplemental material
Cell Cycle
Volume 17, 2018 - Issue 8
Related Research Data
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Source:
Informa UK Limited
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
Source:
American Association for Cancer Research (AACR)
2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.
Source:
Elsevier BV
Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma
Source:
Elsevier BV
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Source:
MDPI AG
Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Source:
Elsevier BV
A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.
Source:
AME Publishing Company
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
Source:
BioMed Central
HDAC expression and clinical prognosis in human malignancies
Source:
Elsevier BV
Histone deacetylases (HDACs): characterization of the classical HDAC family
Source:
Portland Press Ltd.
Long-term safety of cladribine in MALT lymphoma
Source:
Wiley
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Source:
American Association for Cancer Research (AACR)
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
Source:
Springer Science and Business Media LLC
Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK‐LGL leukaemia
Source:
Wiley
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Source:
Springer Nature
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma
Source:
Informa Healthcare
Improved survival in multiple myeloma and the impact of novel therapies
Source:
American Society of Hematology
Anticancer activities of histone deacetylase inhibitors.
Source:
Springer Science and Business Media LLC
Histone deacetylases
Source:
Wiley
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Source:
American Society of Hematology
Epigenetic Therapy as a Putative Molecular Target to Modulate B Cell Biology and Behavior in the Context of Immunological Disorders.
Source:
Hindawi Limited
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells
Source:
Figshare
Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Source:
American Society of Hematology
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Source:
Elsevier BV
Linking provided by
